Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to 47.08%.

  • Apellis Pharmaceuticals' EBITDA Margin rose 761500.0% to 47.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.5%, marking a year-over-year increase of 397600.0%. This contributed to the annual value of 25.29% for FY2024, which is 1086700.0% up from last year.
  • Apellis Pharmaceuticals' EBITDA Margin amounted to 47.08% in Q3 2025, which was up 761500.0% from 23.34% recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year EBITDA Margin high stood at 47.08% for Q3 2025, and its period low was 35216.69% during Q2 2021.
  • Its 5-year average for EBITDA Margin is 2405.21%, with a median of 127.9% in 2023.
  • The largest annual percentage gain for Apellis Pharmaceuticals' EBITDA Margin in the last 5 years was 342541200bps (2022), contrasted with its biggest fall of -4774300bps (2022).
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' EBITDA Margin stood at 245.5% in 2021, then tumbled by -194bps to 722.94% in 2022, then soared by 91bps to 62.2% in 2023, then skyrocketed by 72bps to 17.18% in 2024, then surged by 374bps to 47.08% in 2025.
  • Its EBITDA Margin stands at 47.08% for Q3 2025, versus 23.34% for Q2 2025 and 55.14% for Q1 2025.